Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
Authors:
- 12 February 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (9) , 1834-1838
Abstract
Background: Xp11 translocation renal cell carcinoma (RCC) is an RCC subtype affecting 15% of RCC patients Patients and methods: Patients with Xp11 translocation/TFE3 fusion gene metastatic RCC who had received targeted therapy were identified. Nuclear TFE3 positivity was confirmed by reviewing pathology slides. Responses according to RECIST criteria, progression-free survival (PFS), and overall survival (OS) were analyzed. Results: Overall, 53 patients were identified; 23 had metastatic disease, and of these 21 had received targeted therapy (median age 34 years). Seven patients achieved an objective response. In first line, median PFS was 8.2 months [95% confidence interval (CI) 2.6–14.7 months] for sunitinib (n = 11) versus 2 months (95% CI 0.8–3.3 months) for cytokines (n = 9) (log-rank P = 0.003). Results for further treatment (second, third, or fourth line) were as follows: all three patients receiving sunitinib had a partial response (median PFS 11 months). Seven of eight patients receiving sorafenib had stable disease (median PFS 6 months). One patient receiving mTOR inhibitors had a partial response and six patients had stable disease. Median OS was 27 months with a 19 months median follow-up. Conclusion: In Xp11 translocation RCC, targeted therapy achieved objective responses and prolonged PFS similar to those reported for clear-cell RCC.Keywords
This publication has 17 references indexed in Scilit:
- An aggressive course of Xp11 translocation renal cell carcinoma in a 28‐year‐old manInternational Journal of Urology, 2009
- Adult Xp11 Translocation Renal Cell Carcinoma Diagnosed by Cytogenetics and ImmunohistochemistryClinical Cancer Research, 2009
- Response to Sunitinib Malate in Advanced Alveolar Soft Part SarcomaClinical Cancer Research, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course possible Xp11.2 translocationPathology, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- RECIST revisited: A review of validation studies on tumour assessmentEuropean Journal of Cancer, 2006
- Renal Carcinoma-associated Transcription Factors TFE3 and TFEB Are Leukemia Inhibitory Factor-responsive Transcription Activators of E-cadherinJournal of Biological Chemistry, 2005
- Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2Cancer Genetics and Cytogenetics, 2003
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002